Overview
Sunshine Holdings is a diversified conglomerate spanning healthcare, consumer goods and agribusiness. Healthcare is the largest operating area, while the group also owns distribution, branded consumer products, tea, confectionery, palm oil and dairy businesses.
The key current change is that strong top-line growth has not translated into earnings growth. The latest quarter shows weaker margins across every level, leaving execution in healthcare and the newer pharmaceutical manufacturing and agri initiatives central to the investment case.
Price performance
The share fell 10.2% over three months and 14.4% over six months, versus ASPI declines of 7.1% and 10.6%. Over one year it gained 3.5%, still behind the ASPI's 9.5% return. The last closing price was LKR 29.70 as at 7 August 2026.
The stock sits 24.0% below its 52-week high and only 10.8% above its low, placing it at 23.6% of its own annual range. Recent volatility was 25.6%, 25.9% below the company's own one-year level, while 20-day volume was 45.7% below its 60-day average. The three-month decline occurred alongside no company news in the latest 30-day period, so the data does not establish a cause.
Valuation
Sunshine trades well above diversified-holdings valuation norms: its P/E of 19.15 is at the 88th sector percentile against a 10.74 median, and its P/B of 3.01 is at the 100th percentile against 1.17. The premium is difficult to dismiss because annual ROE is 15.3%, but that return does not offset the earnings slowdown by itself.
The 6.1% dividend yield is at the 94th sector percentile. The payout has been rising, from LKR 0.75 per share in FY24 to LKR 0.975 in FY25 and LKR 1.8 in FY26, but the latest payout ratio is 116.0% and dividend cover is only 0.86 times. The yield therefore comes with limited earnings cover.
News and sentiment
Coverage was normal over the 90-day window, with 13 material articles split between six positive, one negative and six neutral. The most consequential development was the June joint venture with Zydus Lifesciences to build a US$20 million pharmaceutical manufacturing plant in Horana, supporting local production and reducing import reliance.
Coverage then became unusually quiet: zero articles appeared in the latest 30 days versus an own baseline of 3.2 per month. Confirmed actions include the 1:4 share subdivision ex-date of 19 February 2025 and FY26 dividend ex-dates of 17 November 2025, 19 February 2026 and 26 June 2026.
Financials
In the quarter ended 30 June 2026, revenue grew 16.6% year-on-year to LKR 18.5 billion, but operating profit fell 7.7% and net profit fell 15.2%. Gross margin declined from 31.8% to 28.1%, operating margin from 16.6% to 13.2%, and net margin from 10.4% to 7.6%.
This was the worst of seven comparable June quarters for gross, operating and net margin. The LKR 1.03 billion gap between operating profit and net profit also remained material, so finance costs, tax and other below-operating items continued to remove a substantial portion of operating earnings.
For FY26, revenue grew 11.2% to LKR 65.9 billion while net profit fell 14.8% to LKR 5.04 billion. The share subdivision increased outstanding shares to 1.97 billion from about 492 million, so historical EPS comparisons are mechanically affected and absolute profit is the better measure of performance.
Risks
The largest risk is that weaker profitability is accompanied by imperfect cash conversion. FY26 gearing was 47.8% of owners' equity, interest cover was 12.94 times, and the current ratio was 1.73, so leverage and short-term liquidity are currently manageable. However, cash conversion was only 0.84 times, meaning operating profit did not arrive fully as cash.
Minority interests also matter: 39.4% of FY26 group profit belonged to non-controlling shareholders, so group net profit is materially larger than the profit attributable to the shares being valued. Total debt was LKR 9.53 billion.
Healthcare accounts for 57% of reported segment revenue and remains exposed to pricing and trade-policy changes. Consumer retail, representing 29%, faces the reported inflation and fuel-cost backdrop, while the 14% agri exposure carries export, labour and exchange-rate sensitivity.
Outlook
The next specific information point is the quarter ending 30 September 2026. As at 8 August 2026, the filing is expected from 28 October 2026 and by 26 January 2027; it will supersede the June figures used here. That filing will show whether the June margin compression was contained or extended, but this report cannot determine the earnings contribution or timing of the Zydus manufacturing venture.
The healthcare sector backdrop includes phased tariff reform and industry efforts to expand pharmaceutical manufacturing, while consumer and agri businesses face higher inflation and labour constraints. These are operating conditions rather than company announcements, so their effect on Sunshine remains unmeasured in the supplied data.